Literature DB >> 20575124

Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Anna Czarna1, Barbara Beck, Stuti Srivastava, Grzegorz M Popowicz, Siglinde Wolf, Yijun Huang, Michal Bista, Tad A Holak, Alexander Dömling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20575124      PMCID： PMC3772515          DOI： 10.1002/anie.201001343

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  33 in total

1.  Novel multicomponent reaction for the combinatorial synthesis of 2-imidazolines.

Authors:  Robin S Bon; Chongen Hong; Marinus J Bouma; Rob F Schmitz; Frans J J de Kanter; Martin Lutz; Anthony L Spek; Romano V A Orru
Journal:  Org Lett       Date:  2003-10-02       Impact factor: 6.005

2.  Making "real" molecules in virtual space.

Authors:  György Pirok; Nóra Maté; Jeno Varga; József Szegezdi; Miklós Vargyas; Szilard Dórant; Ferenc Csizmadia
Journal:  J Chem Inf Model       Date:  2006 Mar-Apr       Impact factor: 4.956

3.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.

Authors:  Anna Czarna; Grzegorz M Popowicz; Aleksandra Pecak; Siglinde Wolf; Grzegorz Dubin; Tad A Holak
Journal:  Cell Cycle       Date:  2009-04-16       Impact factor: 4.534

4.  Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.

Authors:  Edgar Jacoby; Andreas Boettcher; Lorenz M Mayr; Nathan Brown; Jeremy L Jenkins; Joerg Kallen; Caroline Engeloch; Ulrich Schopfer; Pascal Furet; Keiichi Masuya; Joanna Lisztwan
Journal:  Methods Mol Biol       Date:  2009

5.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

7.  Charge distribution from a simple molecular orbital type calculation and non-bonding interaction terms in the force field MAB.

Authors:  P R Gerber
Journal:  J Comput Aided Mol Des       Date:  1998-01       Impact factor: 3.686

8.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

9.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry.

Authors:  P R Gerber; K Müller
Journal:  J Comput Aided Mol Des       Date:  1995-06       Impact factor: 3.686

10.  Robust NMR screening for lead compounds using tryptophan-containing proteins.

Authors:  Michal Bista; Kaja Kowalska; Weronika Janczyk; Alexander Dömling; Tad A Holak
Journal:  J Am Chem Soc       Date:  2009-06-10       Impact factor: 15.419
View more
  43 in total

Review 1.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

2.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

Review 3.  Focusing on shared subpockets - new developments in fragment-based drug discovery.

Authors:  Eman M M Abdelraheem; Carlos J Camacho; Alexander Dömling
Journal:  Expert Opin Drug Discov       Date:  2015-08-21       Impact factor: 6.098

4.  Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators.

Authors:  Jean-Claude M Rwigema; Barbara Beck; Wei Wang; Alexander Doemling; Michael W Epperly; Donna Shields; Julie P Goff; Darcy Franicola; Tracy Dixon; Marie-Céline Frantz; Peter Wipf; Yulia Tyurina; Valerian E Kagan; Hong Wang; Joel S Greenberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-13       Impact factor: 7.038

5.  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.

Authors:  Constantinos G Neochoritis; Jack Atmaj; Aleksandra Twarda-Clapa; Ewa Surmiak; Lukasz Skalniak; Lisa-Maria Köhler; Damian Muszak; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Barbara Beck; Tad A Holak; Alexander Dömling
Journal:  Eur J Med Chem       Date:  2019-08-06       Impact factor: 6.514

6.  Transient protein states in designing inhibitors of the MDM2-p53 interaction.

Authors:  Michal Bista; Siglinde Wolf; Kareem Khoury; Kaja Kowalska; Yijun Huang; Ewa Wrona; Marcelino Arciniega; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Structure       Date:  2013-10-24       Impact factor: 5.006

7.  MDMX contains an autoinhibitory sequence element.

Authors:  Michal Bista; Miriana Petrovich; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

8.  Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Authors:  Edwin Kroon; Jörg O Schulze; Evelyn Süß; Carlos J Camacho; Ricardo M Biondi; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2015-09-04       Impact factor: 15.336

9.  The p53-MDM2/MDMX axis - A chemotype perspective.

Authors:  Kareem Khoury; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

Review 10.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.